| 132 | 0 | 18 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 建立卡瑞利珠单抗合理应用评价标准,评价临床使用情况,为临床合理用药提供参考。方法 以建立的卡瑞利珠单抗药物利用评价标准为基础,分析2022年1月至2023年6月卡瑞利珠单抗的使用现状并对其合理性进行评价。结果 最终纳入74例住院患者,使用卡瑞利珠单抗206例次,其不合理用药体现在以下方面:无适应证用药(22例次,占10.68%),给药方法不适宜(18例次,占8.74%),有药物相互作用(15例次,占7.28%),病历中未记录相关病理结果(14例次,占6.79%),药物预处理不适宜(2例次,占0.97%)。结论 药师需结合最新的循证证据及医院的用药特点,逐步更新完善临床合理性评价标准,规范实施点评细则,以促进临床合理用药。
Abstract：AIM To establish the evaluation criteria for the rational use of camrelizumab, evaluate the clinical use of camrelizumab, and provide reference for clinical rational drug use. METHODS Based on the evaluation criteria for drug utilization of camrelizumab established, the current status of use of camrelizumab from January 2022 to June 2023 was analyzed and its rationality was evaluated. RESULTS Finally, 74 patients were enrolled, and camrelizumab was administered for 206 times. Irrational use of carrilizumab was reflected in the following aspects: no indications of drug use(22 patients, 10.68%), inappropriate administration method(18 patients, 8.74%), drug interaction(15 patients, 7.28%),no pathological results recorded in medical records(14 cases, 6.79%), and inappropriate drug pretreatment(2 patients,0.97%). CONCLUSION Pharmacists need to gradually update and improve the clinical rationality evaluation criteria based on the latest evidence-based evidence and the characteristics of hospital medication, standardize the implementation of prescription review rules, and promote clinical rational drug use.
[1]卡瑞利珠单抗药品说明书[EB/OL].(2023-02-03)[2023-03-20].https://drugs.dxy.cn/drug/fpuDF4rIvReHE9FqkeQe9Q==.
[2]徐瑞华,李进,马军.中国临床肿瘤学会(CSCO)常见恶性肿瘤诊疗指南2022[M].北京:人民卫生出版社, 2022:15-45.
[3]中国临床肿瘤学会指南工作委员会组织.中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2021[M].北京:人民卫生出版社, 2021:28-56.
[4]国家卫生健康委.抗肿瘤药物临床应用管理办法(试行)[EB/OL].(2020-12-28)[2023-03-20]. http://www.nhc.gov.cn/yzygj/s7659/202012/a7600740bed44d1db7015ca5a1be2cc0.shtml.
[5]国家卫生健康委员会.新型抗肿瘤药物临床应用指导原则(2022年版)[EB/OL].(2022-12-30)[2023-03-20].http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
[6]国家卫生健康委员会.抗肿瘤药物临床合理应用管理指标(2021年版)[EB/OL].(2021-06-28)[2023-03-20]. http:∥www.nhc.gov.cn/yzygj/s7659/202106/43a10d8cc7d043f4ab07890a5f4dd11a/files/5e75f945ba06424bbc2d4e32649d2042.Pdf.
[7]CHEN X F, WU X F, WU H, et al. Camrelizumab plus gemcitabine and oxaliplatin(GEMOX)in patients with advanced biliary tract cancer:a single-arm, open-label, phase II trial[J]. J Immunother Cancer, 2020, 8(2):e001240.
[8]CHEN X N, QIN S K, GU S Z, et al. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer:a multicenter, phase 2 trial[J]. Int J Cancer,2021, 149(11):1944.
[9]QIN S K, CHEN Z D, LIU Y, et al. A phase II study of anti-PD-1antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019,37(Suppl 15):4074.
[10]LIN Z, CAI M, ZHANG P, et al.PhaseⅡ, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J].J Immunother Cancer, 2021, 9(11):e003554.
[11]PENG Z, WEI J, WANG F, et al.Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as firstline therapy for advanced gastric or gastroesophageal junction adenocarcinoma[J].Clin Cancer R es, 2021, 27(11):3069.
[12]LIU J Q, LIU Q, LI Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer:an open-label phase II trial[J]. J Immunother Cancer, 2020,8(1):e000696.
[13]LIU J Q, WANG Y, TIAN Z L, et al. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer[J].Nat Commun, 2022, 13(1):3011.
[14]LAN C, SHEN J, WANG Y, et al.Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer(CLAP):A Multicenter,Open-Label,Single-Arm,PhaseⅡTrial[J].J Clin Oncol,2020,38(34):4095.
[15]US Department of Health and Human Services.Common terminology criteria for adverse events(CTCAE)version 5.0[EB/OL].(2017-11-27)[2023-03-20].https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
[16]RICCIUTI B, DAHLBERG S E, ADENI A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications[J]. J Clin Oncol, 2019, 37(22):1927.
[17]ARBOUR K C, MEZQUITA L, LONG N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(28):2872.
[18]SCOTT S C, PENNELL N A. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab[J]. J Thorac Oncol, 2018, 13(11):1771.
[19]PINATO D J, HOWLETT S, OTTAVIANI D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J]. JAMA Oncol, 2019, 5(12):1774.
[20]CHEUNG K S, LAM L K, SETO W K, et al. Use of antibiotics during immune checkpoint inhibitor treatment is associated with lower survival in hepatocellular carcinoma[J]. Liver Cancer,2021, 10(6):606.
[21]中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤药物治疗相关恶心呕吐防治专家共识(2022年版)[J].中华医学杂志, 2022, 102(39):3080.
[22]广东省药学会.医疗机构超药品说明书用药管理专家共识[J].今日药学, 2014, 24(12):841.
[23]杨敏,劳海燕,曾英彤.医疗机构超药品说明书用药管理专家共识[J].中国现代应用药学, 2017, 34(03):436.
基本信息:
DOI：10.19577/j.1007-4406.2023.07.004
中图分类号:R969
引用信息:
[1]杨梓,杨群.某院卡瑞利珠单抗使用现状及合理性评价[J].中国临床药学杂志,2023,32(07):504-509.DOI:10.19577/j.1007-4406.2023.07.004.
基金信息: